Advertisement vbandhakavi, Author at Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

All articles by vbandhakavi 

AbbVie agrees to acquire ImmunoGen for around $10.1bn

ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The deal will see ImmunoGen’s follow-on pipeline of next-generation ADCs complement the ADC platform and